Buformin
From Wikipedia, the free encyclopedia
 |
|
|
Buformin
|
|
| Systematic (IUPAC) name | |
| 2-butyl-1-(diaminomethylidene)guanidine | |
| Identifiers | |
| CAS number | |
| ATC code | A10 |
| PubChem | |
| Chemical data | |
| Formula | C6H15N5 |
| Mol. mass | 157.217 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | Renal |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status |
Withdrawn in most countries |
| Routes | Oral |
Buformin is an anti-diabetic drug of the biguanide class, chemically related to metformin and phenformin. It was withdrawn from the market in most countries due to a high risk of causing lactic acidosis.[1][2]
[edit] References
- ^ Verdonck L, Sangster B, van Heijst A, de Groot G, Maes R (1981). "Buformin concentrations in a case of fatal lactic acidosis". Diabetologia 20 (1): 45–6. PMID 7202882.
- ^ Deppermann D, Heidland A, Ritz E, Hörl W (1978). "[Lactic acidosis--a possible complication in buformin-treated diabetics (author's transl)]". Klin Wochenschr 56 (17): 843-53. PMID 713413.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
